- Home
- TOL vs INCY Comparison
TOL vs INCY Comparison
Compare TOL & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOL
- INCY
- Stock Information
- Founded
- TOL 1967
- INCY 1991
- Country
- TOL United States
- INCY United States
- Employees
- TOL N/A
- INCY N/A
- Industry
- TOL Homebuilding
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- TOL Consumer Discretionary
- INCY Health Care
- Exchange
- TOL Nasdaq
- INCY Nasdaq
- Market Cap
- TOL 13.8B
- INCY 17.0B
- IPO Year
- TOL N/A
- INCY 1993
- Fundamental
- Price
- TOL $126.51
- INCY $104.52
- Analyst Decision
- TOL Buy
- INCY Buy
- Analyst Count
- TOL 15
- INCY 19
- Target Price
- TOL $150.87
- INCY $89.19
- AVG Volume (30 Days)
- TOL 965.2K
- INCY 2.8M
- Earning Date
- TOL 12-08-2025
- INCY 10-28-2025
- Dividend Yield
- TOL 0.79%
- INCY N/A
- EPS Growth
- TOL N/A
- INCY 3878.02
- EPS
- TOL 13.61
- INCY 5.90
- Revenue
- TOL $10,876,787,000.00
- INCY $4,813,105,000.00
- Revenue This Year
- TOL $0.45
- INCY $19.33
- Revenue Next Year
- TOL N/A
- INCY $10.47
- P/E Ratio
- TOL $9.29
- INCY $17.60
- Revenue Growth
- TOL 3.26
- INCY 18.09
- 52 Week Low
- TOL $86.67
- INCY $53.56
- 52 Week High
- TOL $169.52
- INCY $109.28
- Technical
- Relative Strength Index (RSI)
- TOL 32.58
- INCY 68.82
- Support Level
- TOL $131.00
- INCY $103.77
- Resistance Level
- TOL $137.25
- INCY $109.28
- Average True Range (ATR)
- TOL 3.16
- INCY 3.82
- MACD
- TOL -0.86
- INCY -0.06
- Stochastic Oscillator
- TOL 19.56
- INCY 75.05
About TOL Toll Brothers Inc.
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Traditional homebuilding operations represent most of company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US. It has its headquarters in Horsham, Pennsylvania.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.